• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Myriad’s breast cancer diagnostic wins approval in Japan

April 2, 2018 By Sarah Faulkner

Myriad GeneticsMyriad Genetics (NSDQ:MYGN) subsidiary Myriad Genetics Laboratories said today that the Japanese Ministry of Health, Labor & Welfare approved its Bracanalysis Diagnostic System to be used with Lynparza – a breast cancer drug marketed by AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK).

Lynparza is a PARP inhibitor designed to target deficiencies in DNA damage response pathways. AstraZeneca and Merck are working to get the drug cleared in Japan to treat patients with BRCA-mutated metastatic breast cancer. Myriad’s Bracanalysis test is the first test approved in Japan for use with a PARP inhibitor, the company touted.

In the U.S., the FDA first approved Myriad’s diagnostic, marketed as Bracanalysis CDx, in Dec. of 2014 for patients with advanced ovarian cancer. Myriad snagged another indication earlier this year for patients with HER2-negative metastatic breast cancer.

The diagnostic test categorizes a patient’s DNA sequence variations in the BRCA1 and BRCA2 genes into five classes, according to Myriad: deleterious, suspected deleterious, variant of uncertain significance, favor polymorphism or polymorphism. Those results are sent to medical personnel to decide if the patient is eligible for treatment with a companion drug.

Myriad and AstraZeneca inked a partnership in 2007 to develop a companion diagnostic for Lynparza.

“Our long-standing collaboration with Myriad Genetics Inc. has now delivered an innovative companion diagnostic to breast cancer patients in Japan, demonstrating our shared ambition to target precision medicines to the right patients across the globe,” Dr. Ruth March, AstraZeneca’s senior VP & head of precision medicine & genomics, said in prepared remarks.

“Receiving regulatory approval in Japan is a major milestone for the company and reflects the high quality standards inherent in all of our laboratory tests,” Gary King, EVP of international operations, added. “As the only approved test in Japan, we will collaborate with our commercial partners to ensure patients with metastatic breast cancer have broad access to Bracanalysis and Lynparza, once it is approved.”

Myriad estimates there are 40,000 patients with metastatic disease in Japan that would be eligible for testing with its Bracanalysis system. The company plans to commercialize the test in an exclusive deal with SRL Inc., one of the largest lab service providers in Japan.

“Breast cancer doctors in Japan can offer BRACAnalysis to their patients with metastatic breast cancer to determine if the carry germline BRCA1 or BRCA2 gene mutations,” Dr. Johnathan Lancaster, gynecological oncologist & Myriad’s CMO, said.  “Importantly, patients who are found to carry a BRCA mutation could soon be considered for treatment with Lynparza.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diagnostics, Featured, Oncology, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: AstraZeneca plc, Merck, myriadgenetics

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS